The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EORTC CLTF 2021 | The benefits of improving tumor cell quantification in CTCL
Maarten Vermeer, MD, PhD, Leiden University Medical Center, Leiden, Netherlands, outlines unmet needs in cutaneous T-cell lymphoma, highlighting challenges around the quantification of tumor cells in CTCL, due to heterogeneity in cell surface markers both between and within individual patients. Dr Vermeer also comments on how improving tumor cell quantification could be used to enhance therapeutic approaches such as extracorporeal photopheresis and mogamulizumab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
